Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pilling, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pilling, A. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Role of the Toxicologic Pathologist in the Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals

Andrew M. Pilling

Molecular Pathology Group, Medicines Safety Evaluation Division, Glaxo Wellcome Research and Development Ltd., Park Road, Ware, Hertfordshire, United Kingdom, amp1069{at}ggr.co.uk.

Biotechnology-derived pharmaceuticals, or biopharmaceuticals, represent a special class of complex, high-molecular weight products, such as monoclonal antibodies, recombinant proteins, and nucleic acids. With these compounds, it is not appropriate to follow conventional safety testing programs, and the preclinical "package" for each biopharmaceutical needs to be individually designed. In addition to standard histopathology, the use of molecular pathology techniques is often required either in conventional animal studies or in in vitro tests. In this review, the safety evaluation of biopharmaceuticals is discussed from the perspective of the toxicologic pathologist, and appropriate examples are given of the use of molecular pathology procedures. Examples include the use of in situ hybridization to localize gene therapy vectors, the assessment of vector integration into genomic DNA by the polymerase chain reaction (PCR), and the use of immunohistochemistry to evaluate the potential cross-reactivity of monoclonal antibodies. In situ PCR techniques may allow for confirmation of the germ cell localization of nucleic acids and may therefore facilitate the risk assessment of germline transmission. Increased involvement with biopharmaceuticals will present challenging opportunities for the toxicologic pathologist and will allow for much greater use of molecular techniques, which have a critical role in the preclinical development of these compounds.

Key Words: Molecular pathology • monoclonal antibodies • recombinant proteins • gene therapies • nucleic acids

References

  • Adams JC (1992). Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J. Histochem. Cytochem. 40: 1457-1463.[Abstract]
  • Agrawal S. and Zhao Q. (1998). Mixed backbone oligonucleotides: Improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev. 8: 135-139.[Web of Science][Medline] [Order article via Infotrieve]
  • Beard CW and Mason PW (1998). Out on the farm with DNA vaccines. Nat. Biotechnol. 16: 1325-1328.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brody SL, Metzger M., Danel C., Rosenfeld MA, and Crystal RG (1992). Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5: 821-836.
  • Buckel P. (1996). Recombinant proteins for therapy. Trends Pharmacol. Sci. 17: 450-456.[CrossRef][Medline] [Order article via Infotrieve]
  • Burdick JF, Pennington LR, Smith W., Irwin B., and Williams GM (1987). Reversal of progressive renal allograft dysfunction with OKT3. Nephron 46: 52-55.[Web of Science][Medline] [Order article via Infotrieve]
  • Burnett R., Guichard Y., and Barale E. (1997). Immunohistochemistry for light microscopy in safety evaluation of therapeutic agents: An overview. Toxicology 119: 83-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Butler M., Stecker K., and Bennett CF (1997). Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77: 379-388.[Web of Science][Medline] [Order article via Infotrieve]
  • Caplen NJ, Alton Ewfw, Middleton PG, Dorin JR, Stevenson BJ, Gao X., Durham SR, Jeffery PK, Hodson ME, Coutelle C., Huang L., Porteous DJ, Williamson R., and Geddes DM (1995). Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat. Med. 1: 39-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cline MJ, Stang H., Mercola K., Morse L., Ruprecht R., Browne J., and Salser W. (1980). Gene transfer in intact animals. Nature 284: 422-425.[CrossRef][Medline] [Order article via Infotrieve]
  • Dempster M. (1998). Designing non-clinical safety evaluation programmes: The view of the toxicologist. In: Safety Evaluation of Biotechnologically-Derived Pharmaceuticals: Facilitating a Scientific Approach, SA Griffiths and CE Lumley (eds), Kluwer Academic Publishers, London, UK, pp. 7-15.
  • Desjardins JP, Sproat BS, Beijer B., Blaschke M., Dunkel M., Gerdes W., Ludwig J., Reither V., Rupp T., and Iversen PL (1996). Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. J. Pharmacol. Exp. Ther. 278: 1419-1427.[Abstract/Free Full Text]
  • Editorial ( 1999). Gene therapy and the germline. Nat. Med. 5: 245.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ellington AD and Conrad R. (1995). Aptamers as potential nucleic acid pharmaceuticals. Biotechnol. Annu. Rev. 1: 185-214.[Medline] [Order article via Infotrieve]
  • Ellington AD and Szostak JW (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.[CrossRef][Medline] [Order article via Infotrieve]
  • European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products ( 1998). Safety studies for gene therapy products: Annex to note for guidance on gene therapy product quality aspects in the production of vectors and genetically modified somatic cells. Report No. SWP/112/98, European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products, pp. 1-7.
  • Farrell GC (1991). Treatment of chronic hepatitis C with alpha interferon. J. Gastroenterol. Hepatol. 6: 36-40.[Web of Science][Medline] [Order article via Infotrieve]
  • Food and Drug Administration ( 1997). Panel to investigate possible germline transfer in gene therapy work. FDA Week 3: 1-2.
  • Food and Drug Administration, Center for Biologics Evaluation and Research (1996). Points to consider on plasmid DNA vaccines for preventive infectious disease indications. Fed. Reg. 61: 68269. Available at: http://www.fda.gov/cber.
  • Food and Drug Administration, Center for Biologics Evaluation and Research (1997). Points to consider in the manufacture and testing of monoclonal antibody products for human use. Fed. Reg. 62: 9196. Available at: http://www.fda.gov/cber.
  • Food and Drug Administration, Center for Biologics Evaluation and Research (1998). Guidance for industry: Guidance for human somatic cell therapy and gene therapy. Fed. Reg. 63: 36413. Available at: http://www.fda.gov/cber.
  • Food and Drug Administration, Center for Biologics Evaluation and Research (1999). General guidance available at: http://www.nih-gov/od/orda/3-99sum.htm.
  • Fox S. (1997). Gene therapy under the spotlight. Pharm. Forum 8: 5-7.
  • Friedmann T. (1989). Progress toward human gene therapy. Science 244: 1275-1281.[Abstract/Free Full Text]
  • Gillett NA and Chan CM (1999). Molecular pathology in the preclinical development of biopharmaceuticals. Toxicol. Pathol. 27: 48-52.[Abstract/Free Full Text]
  • Griffiths SA and Lumley CE (1998). Non-clinical safety studies for biotechnologically-derived pharmaceuticals: Conclusions from an international workshop. Hum. Exp. Toxicol. 17: 63-83.[Free Full Text]
  • Hansen B., Lernmark A., Nielsen JH, Owerbach D., and Welinder B. (1982). New approaches to therapy and diagnosis of diabetes. Diabetologia 22: 61-67.[Web of Science][Medline] [Order article via Infotrieve]
  • Henry SP, Monteith D., and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 12: 395-408.[Medline] [Order article via Infotrieve]
  • Ho PT and Parkinson DR (1997). Antisense oligonucleotides as therapeutics for malignant diseases. Semin. Oncol. 24: 187-202.[Web of Science][Medline] [Order article via Infotrieve]
  • Hsu S., Raine L., and Fanger H. (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 29: 577-580.[Abstract]
  • Huber BE, Richards CA, and Austin EA (1994). Virus-directed enzyme/prodrug therapy (VDEPT). Selectively engineering drug sensitivity into tumors. Ann. NY Acad. Sci. 716: 104-114.[Web of Science][Medline] [Order article via Infotrieve]
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1998). Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. Proceedings of the Fourth International Conference, Brussels, 1997, PF D'Arcy and DWG Harron (eds), Queens University Press, Belfast, Ireland, pp. 877-908.
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1998). Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Proceedings of the Fourth International Conference, Brussels, 1997, PF D'Arcy and DWG Harron (eds), Queens University Press, Belfast, Ireland, pp. 1045-1056.
  • Irshad M. (1998). Nucleic acid hepatitis B virus (HBV) vaccine: Current status. Hepatol. Res. 13: 71-79.[CrossRef][Web of Science]
  • Klinman DM, Yi A., Beaucage SL, Conover J., and Krieg AM (1996). CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12 and IFNg. Proc. Natl. Acad. Sci. USA 93: 2879-2883.[Abstract/Free Full Text]
  • Kohler G. and Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.[CrossRef][Medline] [Order article via Infotrieve]
  • Kurth R. (1995). Risk potential of the chromosomal insertion of foreign DNA. Ann. NY Acad. Sci. 772: 140-151.[Web of Science][Medline] [Order article via Infotrieve]
  • MacCallum DE, Hupp TR, Midgley CA, Stuart D., Campbell SJ, Harper A., Walsh FS, Wright EG, Balmain A., Lane DP, and Hall P. (1996). The p53 response to ionizing radiation in adult and developing murine tissues. Oncogene 13: 2575-2587.[Web of Science][Medline] [Order article via Infotrieve]
  • Meager A. and Robertson JS (1998). Regulatory and standardization issues for DNA and vectored vaccines. Curr. Res. Mol. Therapeutics 1: 262-265.
  • Monteith DK and Levin AA (1999). Synthetic oligonucleotides: The development of antisense therapeutics. Toxicol. Pathol. 27: 8-13.[Abstract/Free Full Text]
  • Mor G., Singla M., Steinberg AD, Hoffman SL, Okuda K., and Klinman DM (1997). Do DNA vaccines induce autoimmune disease? Hum. Gene Ther. 8: 293-300.[Web of Science][Medline] [Order article via Infotrieve]
  • Nichols WW, Ledwith BJ, Manam SV, and Troilo PJ (1995). Potential DNA vaccine integration into host cell genome. Ann. NY Acad. Sci. 772: 30-39.[Web of Science][Medline] [Order article via Infotrieve]
  • Palu G., Bonaguro R., and Marcello A. (1999). In pursuit of new developments for gene therapy of human diseases. J. Biotechnol. 68: 1-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Peterson NC (1996). Recombinant antibodies: Alternative strategies for developing and manipulating murine-derived monoclonal antibodies. Lab. Anim. Sci. 46: 8-13.[CrossRef]
  • Rogers S. (1971). Gene therapy: A potentially invaluable aid to medicine and mankind. Res. Commun. Chem. Pathol. Pharmacol. 2: 587-600.[Web of Science][Medline] [Order article via Infotrieve]
  • Roth MS, Bunn PA, and Foon KA (1988). Interferon therapy for lymphoproliferative disorders. Cancer Treatment Res. 38: 231-252.[Medline] [Order article via Infotrieve]
  • Ryffel B. (1996). Unanticipated human toxicology of recombinant proteins. Arch. Toxicol. 18: 333-341.
  • Schneider H. and Coutelle C. (1999). Commentary: In utero gene therapy. The case for. Nat. Med. 5: 256-257.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stull RA and Szoka FC (1995). Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prospects. Pharm. Res. 12: 465-483.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tang D., DeVit M., and Johnston A. (1992). Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154.[CrossRef][Medline] [Order article via Infotrieve]
  • Tang XB, Hobom G. and Luo D. (1994). Ribozyme mediated destruction of influenza A virus in vitro and in vivo. J. Med. Virol. 42: 385-395.[Web of Science][Medline] [Order article via Infotrieve]
  • Tsukui T., Kanegae Y., Saito I., and Toyoda Y. (1996). Transgenesis by adenovirus-mediated gene transfer into mouse zona-free eggs. Nat. Biotechnol. 14: 982-985.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Van Drunen Little-van den Hurk S., Braun RP, Lewis PJ, Karvonen BC, Baca-Estrada ME, and Snider M. (1998). Intradermal immunization with a bovine herpesvirus-1 DNA vaccine induces protective immunity in cattle. J. Gen. Virol. 79: 831-839.[Abstract]
  • Vaswani SK and Hamilton RG (1998). Humanised antibodies as potential therapeutic drugs. Ann. Allergy Asthma Immunol. 81: 105-115.[Web of Science][Medline] [Order article via Infotrieve]
  • Wagner RW (1995). The state of the art in antisense research. Nat. Med. 1: 1116-1118.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Waldmann TA (1991). Monoclonal antibodies in diagnosis and therapy. Science 252: 1657-1662.[Abstract/Free Full Text]
  • Wolff JA, Malone RW, Williams P., Chong W., Acsadi G., Jani A., and Felgner PL (1989). Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.[CrossRef][Web of Science]
  • Yang XD, Jia XC, Corvalan JR, Wang P., Davis CG, and Jakobovits A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59: 1236-1243.[Abstract/Free Full Text]
  • Ye X., Gao GP, Pabin C., Raper SE, and Wilson JM (1998). Evaluating the potential of germ line transmission after intravenous administration of recombinant adenovirus in the C3H mouse. Hum. Gene Ther. 9: 2135-2142.[Web of Science][Medline] [Order article via Infotrieve]
  • Zamecnik PC and Stephenson ML (1978). Inhibition of rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75: 280-284.[Abstract/Free Full Text]
  • Zaug AJ, Been MD, and Cech TR (1978). The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature 324: 429-433.

Toxicologic Pathology, Vol. 27, No. 6, 678-688 (1999)
DOI: 10.1177/019262339902700610
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
R. A. Ettlin, B. Bolon, I. Pyrah, Y. Konishi, and H. E. Black
Global Recognition of Qualified Toxicologic Pathologists: Where We Are Now and Where We Need to Go
Toxicol Pathol, July 1, 2008; 36(5): 753 - 759.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
M. J. Jayo, D. D. Watson, B. J. Wagner, and T. A. Bertram
Tissue Engineering and Regenerative Medicine: Role of Toxicologic Pathologists for an Emerging Medical Technology
Toxicol Pathol, January 1, 2008; 36(1): 92 - 96.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pilling, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pilling, A. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?